Cationic Peptidomimetic Amphiphiles Having a N-Aryl- or N-Naphthyl-1,2,3-Triazole Core Structure Targeting Clostridioides (Clostridium) difficile: Synthesis, Antibacterial Evaluation, and an In Vivo C. difficile Infection Model
Authors:
- Muni Kumar MahadariMMMuni Kumar Mahadari
- Sreenu JennepalliSJSreenu Jennepalli
- Andrew J. TagueATAndrew J. Tague
- Papanin PutsathitPPPapanin Putsathit
- Melanie L. HuttonMHMelanie L. Hutton
- Katherine A. HammerKHKatherine A. Hammer
- Daniel R. KnightDKDaniel R. Knight
- Thomas V. RileyTRThomas V. Riley
- Dena LyrasDLDena Lyras
- Paul A. KellerPKPaul A. Keller
- Stephen G. PyneSPStephen G. Pyne
Open Access
- 26 July 2021
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 10 (8) , 913
Abstract
Clostridioides (also known as Clostridium) difficile is a Gram-positive anaerobic, spore producing bacterial pathogen that causes severe gastrointestinal infection in humans. The current chemotherapeutic options are inadequate, expensive, and limited, and thus inexpensive drug treatments for C. difficile infection (CDI) with improved efficacy and specificity are urgently needed. To improve the solubility of our cationic amphiphilic 1,1′-binaphthylpeptidomimetics developed earlier that showed promise in an in vivo murine CDI model we have synthesized related compounds with an N-arytriazole or N-naphthyltriazole moiety instead of the 1,1′-biphenyl or 1,1′-binaphthyl moiety. This modification was made to increase the polarity and thus water solubility of the overall peptidomimetics, while maintaining the aromatic character. The dicationic N-naphthyltriazole derivative 40 was identified as a C. difficile-selective antibacterial with MIC values of 8 µg/mL against C. difficile strains ATCC 700057 and 132 (both ribotype 027). This compound displayed increased water solubility and reduced hemolytic activity (32 µg/mL) in an in vitro hemolysis assay and reduced cytotoxicity (CC50 32 µg/mL against HEK293 cells) relative to lead compound 2. Compound 40 exhibited mild efficacy (with 80% survival observed after 24 h compared to the DMSO control of 40%) in an in vivo murine model of C. difficile infection by reducing the severity and slowing the onset of disease.Keywords
Funding Information
- National Health and Medical Research Council (APP1124032)
This publication has 38 references indexed in Scilit:
- The role of toxins in Clostridium difficile infectionFEMS Microbiology Reviews, 2017
- Clostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal EffectsToxins, 2016
- Diversity and Evolution in the Genome of Clostridium difficileClinical Microbiology Reviews, 2015
- New developments in chemotherapeutic options for Clostridium difficile colitisCurrent Opinion in Infectious Diseases, 2013
- Overview of Severe Clostridium difficile InfectionCritical Care Clinics, 2013
- Clostridium difficile infectionCurrent Problems in Surgery, 2013
- Fidaxomicin for treatment of clostridium difficile-associated diarrhea and its potential role for prophylaxisExpert Opinion on Pharmacotherapy, 2013
- Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus VancomycinClinical Infectious Diseases, 2012
- New antibiotics for selective treatment of gastrointestinal infection caused byClostridium difficileExpert Opinion on Therapeutic Patents, 2010
- Treatment of Clostridium difficile-Associated DiseaseGastroenterology, 2009